The chief medical officer at Xenon Pharmaceuticals outlined why azetukalner’s selective potassium channel activation offers a different way to suppress hyperexcitable neuronal circuits in focal epilepsy. [WATCH TIME: 3 minutes]
Christopher Kenney, MD, FAAN
Advertisement
Articles by Christopher Kenney, MD, FAAN
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Overviewing Promising Phase 1/2 Data of Gene Therapy ETX101 in Dravet Syndrome: Joseph Sullivan, MD
2
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
3
Inside the 2026 MDA Conference: Keynote Insights and Evolving Neuromuscular Care
4
Stiripentol Reduces Seizure Burden in Patients with Lennox-Gastaut Syndrome, Study Shows
5
